<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82108">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01657448</url>
  </required_header>
  <id_info>
    <org_study_id>CYSEMS0112</org_study_id>
    <nct_id>NCT01657448</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Acriflavine Hydrochloride + Methenamine + Methylthioninium Chloride vs Placebo for the Rapid Relief of Symptoms Urinary Tract Infection</brief_title>
  <official_title>Parallel Study, Double-blind, Randomized, to Evaluate the Efficacy of the Combination of Drug Versus Placebo of Drug for the Rapid Relief of Symptoms of Uncomplicated Lower Urinary Tract Infection in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the combination of Acriflavine
      hydrochloride + Methenamine + Methylthioninium chloride produced by EMS S/A, using the
      comparator Placebo, the rapid relief of symptoms in uncomplicated lower urinary tract
      infection in women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Open, randomized, prospective study.

        -  Length of experience: 05 days.

        -  04 visits (days 1, 2, 5 and 7).

        -  Evaluation of the efficacy and safety of the medication.

        -  Shall be assessed for symptoms during the first 24 hours as pollakiuria, cystalgia,
           dysuria, urinary urgency and odor through the report of the patients (subjective
           parameter) and objective evaluation through laboratory tests and urine culture Urine I,
           comparing, after 3 days treatment, the results between the groups.

        -  Shall be assessed for adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of treatment in the rapid relief of symptoms in uncomplicated lower urinary tract infection</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptoms will be assessed during the first 24 hours as pollakiuria, cystalgia, dysuria, urinary urgency and odor through the report of the patient (subjective parameter) and objective evaluation through laboratory tests and urine culture Urine I, comparing, after 3 days treatment, the results between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the study medication</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the safety of the study medication on the occurrence, type, intensity and frequency of adverse reactions during the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Lower Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Acriflavine, Methenamine, Methylthioninium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to Acriflavine, Methenamine, Methylthioninium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acriflavine hydrochloride, Methenamine, Methylthioninium chloride</intervention_name>
    <description>• Ingesting two (02) drives the drug with a glass of water, 8 by 8 hours for 3 days</description>
    <arm_group_label>Acriflavine, Methenamine, Methylthioninium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Acriflavine hydrochloride, Methenamine, Methylthioninium chloride</intervention_name>
    <description>• Ingesting two (02) drives the drug with a glass of water, 8 by 8 hours for 3 days</description>
    <arm_group_label>Placebo to Acriflavine, Methenamine, Methylthioninium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who agree to participate by agreeing to the terms proposed in the IC;

          -  Patients aged over 18 years of any ethnicity;

          -  Female patients;

          -  Patients with clinical diagnosis of urinary tract infection (UTI), for symptomatic
             UTI, uncomplicated, with onset of symptoms no more than 72 hours of visit 1;

          -  Women who are using an effective method of birth control (hormonal contraceptives,
             IUDs, surgical sterilization), or who are postmenopausal, in addition to condom use
             (mandatory).

        Exclusion Criteria:

          -  Patients who are febrile (axillary T º: ≥ 38 ° C), with back pain or lumbar;

          -  Patients with suspected STD and / or pelvic inflammatory disease;

          -  Patients with complicated clinical picture of UTI-eligible or systemic antibiotic
             therapy intravenously;

          -  Patients hospitalized and / or bedridden and / or making use of urinary probe;

          -  Patients with any other infectious condition that could confound interpretation of
             clinical response to treatment;

          -  Patients who received systemic antibiotic therapy / parenteral past 30 days;

          -  Patients with a history of allergy or intolerance to any known or suspected one of
             the ingredients of the product under investigation;

          -  Patients who are pregnant or during lactation, or childbearing potential and are not
             making use of effective contraception;

          -  Patients presenting with renal disease or severe liver disease, according to medical
             history and / or laboratory;

          -  Patients presenting with severe systemic disease according to the known medical
             history;

          -  Patients receiving treatment with immunosuppressants, including corticosteroids
             within 30 days before the study began, or who are receiving immunosuppressive
             treatments or who have congenital or acquired immunodeficiency known;

          -  Patients who received antibiotic treatment, anthelmintic within 15 days prior to
             study entry;

          -  Patients unable to understand the guidelines specified in this protocol or can not
             attend all study visits or unable to complete the log;

          -  Patients with a history of alcoholism, drug abuse, psychological or emotional
             problems that would invalidate the Deed of Consent or limit the ability of patients
             to adhere to protocol requirements;

          -  Patients with any direct, familiar or not with professionals involved in conducting
             the study or the EMS S / A;

          -  Patients with uncontrolled hypertension (blood pressure [PA] pressure&gt; 180 mmHg or
             diastolic BP&gt; 100 mmHg) at randomization or clinical hypertensive urgency;

          -  Patients with a prior history of abnormal hematologic, hepatic, renal or metabolic
             functions;

          -  Any finding of clinical observation (history and physical examination) that is
             interpreted by the physician investigator as a risk to the patient's participation in
             the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulisses Magalhães Antunes da Rocha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAEP - Centro Avançado de Estudos e Pesquisa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>FELIPE PINHO, MD</last_name>
    <phone>+ 55 19 9212 7964</phone>
    <email>felipe.pinho@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>CAEP - Centro Avançado de Estudos e Pesquisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13.087-567</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ulisses Magalhães Antunes da Rocha, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 15, 2012</lastchanged_date>
  <firstreceived_date>August 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary infection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acriflavine</mesh_term>
    <mesh_term>Methenamine hippurate</mesh_term>
    <mesh_term>Methenamine</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
